The pooled HR for OS was 1.50 (95% CI: 1.11–2.03, with a p-value of 0.009, I2 = 0%), and the HR for AML transformation was 3.12 (95% CI: 1.36–7.11, with a p-value of 0.007, I2 = 0%) for patients with low- or intermediate-1-IPSS risk MDS with SRSF2 mutations, compared to SRSF2-unmutated patients (Fig 4), indicating that SRSF2 mutations predicted an independent unfavorable prognostic impact in terms of both OS and AML transformation. The gene discussed is SRSF2; the disease is myelodysplastic syndrome.